Drug Overview

Seribantumab is an advanced, experimental cancer treatment designed to block specific signals that allow tumors to grow and survive. It belongs to a modern group of medicines called monoclonal antibodies. This drug is a key example of precision medicine because it focuses on a very specific genetic change found in certain types of cancer.

As an investigational drug, seribantumab is not available for general purchase at a pharmacy. It is currently being tested in clinical trials across the United States and other global markets. Patients can access this medication only by enrolling in a qualified research study under the supervision of an oncologist.

• Generic name: Seribantumab (also known as MM-121)
• US Brand names: None (Investigational drug)
• Drug Class: HER3 (ErbB3) inhibitor, Monoclonal antibody
• Route of Administration: Intravenous (IV) infusion
• FDA Approval Status: Investigational (Granted Fast Track Designation for certain lung cancers)

What Is It and How Does It Work? (Mechanism of Action)

Seribantumab is a Targeted Therapy and a Smart Drug. Unlike traditional chemotherapy that attacks all fast-growing cells, seribantumab is engineered to target a specific “docking station” on the surface of cancer cells called the HER3 receptor.

At the molecular level, the drug works by interfering with a process called the NRG1 (Neuregulin-1) fusion. In some cancers, the NRG1 gene breaks and joins with another gene. This “fusion” creates a constant supply of NRG1 protein, which acts like a key that stays stuck in the HER3 receptor lock. When this happens, the HER3 receptor sends non-stop signals through communication pathways inside the cell, specifically the PI3K/AKT and MAPK/ERK pathways. These signals tell the cancer cell to multiply rapidly and resist dying.

Seribantumab binds directly to the HER3 receptor with high precision. By attaching to the receptor, it physically blocks the NRG1 protein from “turning on” the cell. Furthermore, the drug causes the HER3 receptors to be pulled inside the cell and destroyed. This shuts down the PI3K/AKT and MAPK/ERK signaling pathways, cutting off the cancer’s growth instructions and forcing the tumor to shrink.

FDA Approved Clinical Indications

Because seribantumab is an investigational drug, it does not currently have official FDA-approved indications for general use. It is being studied in clinical trials for the following specific conditions:

Oncological uses

• Investigational treatment for advanced solid tumors that have a confirmed NRG1 gene fusion.
• Investigational treatment for Non-Small Cell Lung Cancer (NSCLC) with NRG1 fusions.
• Investigational treatment for pancreatic, breast, and colorectal cancers carrying the NRG1 fusion.

Non-oncological

• None at this time.

Dosage and Administration Protocols

In clinical research settings, seribantumab is given as a liquid through a needle into a vein. The dosage is usually calculated based on the patient’s body weight.

Dose Adjustments

If a patient experiences severe side effects, doctors may pause the treatment or reduce the weekly dose. Because the drug is a large protein (antibody), it is not primarily cleared by the kidneys or liver in the same way as chemical drugs. However, clinicians monitor liver and kidney function closely. There are no established dose starting rules for renal or hepatic insufficiency outside of specific trial protocols.

Clinical Efficacy and Research Results

Clinical research data from 2020 to 2025 has focused heavily on the CREST trial, which looks at patients with various solid tumors that have the NRG1 fusion.

Numerical data from these studies show that seribantumab is highly active in tumors driven by NRG1. In early reports, the objective response rate (the percentage of patients whose tumors shrank significantly) was approximately 33 percent to 35 percent across different tumor types. In some patients with lung cancer, the drug has shown the ability to stop disease progression for over 9 months, which is a significant result for patients who have already failed multiple other lines of therapy. Researchers are finding that the drug works best when the NRG1 fusion is the primary driver of the cancer.

Safety Profile and Side Effects

Seribantumab has a safety profile that is generally considered manageable compared to traditional chemotherapy.

Black Box Warning

There is no official FDA Black Box Warning for seribantumab because it is an investigational drug.

Common side effects

These occur in more than 10 percent of patients:

• Diarrhea
• Feeling very tired (fatigue)
• Skin rash or dry skin
• Nausea
• Mouth sores (mucositis)

Serious adverse events

• Severe infusion-related reactions (fever, chills, or trouble breathing during the drip)
• Significant drops in white blood cell or platelet counts
• Lung inflammation (pneumonitis)
• Dehydration due to severe diarrhea

Management strategies

To manage diarrhea, doctors often prescribe anti-diarrheal medications like loperamide to be kept on hand. For skin rashes, steroid creams or specialized moisturizers are used. If an infusion reaction occurs, the nurse will slow down or stop the drip and may give antihistamines or steroids to calm the body’s response.

Research Areas

Seribantumab is a major topic of interest in the study of “drug resistance” in regenerative medicine. Cancer stem cells often use the HER3 pathway to survive even when other antennas (like HER1 or HER2) are blocked by different drugs. Researchers are studying how seribantumab can be combined with other targeted therapies or immunotherapies to “double-block” these escape routes. By cutting off the HER3 pathway, scientists hope to prevent cancer stem cells from regenerating the tumor, leading to longer periods of remission.

Patient Management and Practical Recommendations

Pre-treatment tests to be performed

• Genetic testing (specifically RNA-based Next-Generation Sequencing) to confirm the presence of an NRG1 gene fusion.
• Complete blood count (CBC) to check baseline blood levels.
• Liver and kidney function tests.

Precautions during treatment

Patients must be watched closely during the first few infusions for any signs of an allergic reaction. Because the drug can cause diarrhea, maintaining good hydration is essential throughout the treatment period.

Do’s and Don’ts list

• Do report any new or worsening cough or shortness of breath to your care team immediately.
• Do use gentle, fragrance-free soaps and lotions to manage skin dryness.
• Do stay hydrated by drinking at least 8 glasses of water a day.
• Don’t ignore severe diarrhea; call your doctor if it lasts more than 24 hours.
• Don’t start any new medications or herbal supplements without asking your research nurse or doctor first.
• Don’t skip your scheduled blood tests, as they are needed to ensure your bone marrow is healthy.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Seribantumab is an investigational medication and is not approved by the FDA for the treatment of any disease. Always consult with a qualified oncologist or healthcare professional before participating in a clinical trial or starting a new medical treatment.